nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Temozolomide—malignant glioma	0.254	1	CbGbCtD
Pimecrolimus—Condition aggravated—Temozolomide—malignant glioma	0.0156	0.125	CcSEcCtD
Pimecrolimus—MTOR—blood vessel—malignant glioma	0.0132	0.145	CbGeAlD
Pimecrolimus—Sirolimus—FGF2—malignant glioma	0.0105	1	CrCbGaD
Pimecrolimus—MTOR—embryo—malignant glioma	0.00788	0.0864	CbGeAlD
Pimecrolimus—MTOR—brainstem—malignant glioma	0.00722	0.0792	CbGeAlD
Pimecrolimus—MTOR—retina—malignant glioma	0.00697	0.0764	CbGeAlD
Pimecrolimus—MTOR—telencephalon—malignant glioma	0.00641	0.0703	CbGeAlD
Pimecrolimus—FKBP1A—retina—malignant glioma	0.00627	0.0687	CbGeAlD
Pimecrolimus—FKBP1A—telencephalon—malignant glioma	0.00577	0.0632	CbGeAlD
Pimecrolimus—Skin hyperpigmentation—Carmustine—malignant glioma	0.00494	0.0398	CcSEcCtD
Pimecrolimus—FKBP1A—medulla oblongata—malignant glioma	0.00453	0.0497	CbGeAlD
Pimecrolimus—MTOR—spinal cord—malignant glioma	0.00449	0.0493	CbGeAlD
Pimecrolimus—FKBP1A—midbrain—malignant glioma	0.00414	0.0454	CbGeAlD
Pimecrolimus—FKBP1A—spinal cord—malignant glioma	0.00404	0.0443	CbGeAlD
Pimecrolimus—Otitis media—Temozolomide—malignant glioma	0.00365	0.0294	CcSEcCtD
Pimecrolimus—MTOR—central nervous system—malignant glioma	0.00364	0.04	CbGeAlD
Pimecrolimus—MTOR—cerebellum—malignant glioma	0.00356	0.0391	CbGeAlD
Pimecrolimus—FKBP1A—central nervous system—malignant glioma	0.00328	0.0359	CbGeAlD
Pimecrolimus—FKBP1A—cerebellum—malignant glioma	0.0032	0.0351	CbGeAlD
Pimecrolimus—Viral infection—Temozolomide—malignant glioma	0.00314	0.0253	CcSEcCtD
Pimecrolimus—Herpes simplex—Temozolomide—malignant glioma	0.00308	0.0248	CcSEcCtD
Pimecrolimus—MTOR—brain—malignant glioma	0.00289	0.0317	CbGeAlD
Pimecrolimus—Skin exfoliation—Carmustine—malignant glioma	0.00281	0.0226	CcSEcCtD
Pimecrolimus—Influenza like illness—Temozolomide—malignant glioma	0.00276	0.0222	CcSEcCtD
Pimecrolimus—Skin exfoliation—Temozolomide—malignant glioma	0.00271	0.0218	CcSEcCtD
Pimecrolimus—FKBP1A—brain—malignant glioma	0.0026	0.0285	CbGeAlD
Pimecrolimus—Swelling—Carmustine—malignant glioma	0.00242	0.0195	CcSEcCtD
Pimecrolimus—Ear pain—Temozolomide—malignant glioma	0.00242	0.0195	CcSEcCtD
Pimecrolimus—Gastroenteritis—Temozolomide—malignant glioma	0.00233	0.0187	CcSEcCtD
Pimecrolimus—Nasal congestion—Temozolomide—malignant glioma	0.00226	0.0182	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Temozolomide—malignant glioma	0.00219	0.0176	CcSEcCtD
Pimecrolimus—Face oedema—Carmustine—malignant glioma	0.00206	0.0166	CcSEcCtD
Pimecrolimus—Face oedema—Temozolomide—malignant glioma	0.00199	0.016	CcSEcCtD
Pimecrolimus—Breast disorder—Temozolomide—malignant glioma	0.00186	0.015	CcSEcCtD
Pimecrolimus—Bronchitis—Temozolomide—malignant glioma	0.00171	0.0138	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00166	0.0133	CcSEcCtD
Pimecrolimus—Pneumonia—Carmustine—malignant glioma	0.00165	0.0133	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Temozolomide—malignant glioma	0.00163	0.0131	CcSEcCtD
Pimecrolimus—Pneumonia—Temozolomide—malignant glioma	0.0016	0.0129	CcSEcCtD
Pimecrolimus—Infestation NOS—Temozolomide—malignant glioma	0.00159	0.0128	CcSEcCtD
Pimecrolimus—Infestation—Temozolomide—malignant glioma	0.00159	0.0128	CcSEcCtD
Pimecrolimus—Sinusitis—Temozolomide—malignant glioma	0.00149	0.012	CcSEcCtD
Pimecrolimus—Pharyngitis—Temozolomide—malignant glioma	0.00142	0.0114	CcSEcCtD
Pimecrolimus—Eye disorder—Carmustine—malignant glioma	0.00138	0.0111	CcSEcCtD
Pimecrolimus—Flushing—Carmustine—malignant glioma	0.00137	0.011	CcSEcCtD
Pimecrolimus—Eye disorder—Temozolomide—malignant glioma	0.00133	0.0107	CcSEcCtD
Pimecrolimus—Flushing—Temozolomide—malignant glioma	0.00132	0.0107	CcSEcCtD
Pimecrolimus—Immune system disorder—Temozolomide—malignant glioma	0.00129	0.0104	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Temozolomide—malignant glioma	0.00129	0.0104	CcSEcCtD
Pimecrolimus—Malnutrition—Carmustine—malignant glioma	0.00128	0.0104	CcSEcCtD
Pimecrolimus—Erythema—Carmustine—malignant glioma	0.00128	0.0104	CcSEcCtD
Pimecrolimus—Back pain—Carmustine—malignant glioma	0.00124	0.01	CcSEcCtD
Pimecrolimus—Erythema—Temozolomide—malignant glioma	0.00124	0.01	CcSEcCtD
Pimecrolimus—Malnutrition—Temozolomide—malignant glioma	0.00124	0.01	CcSEcCtD
Pimecrolimus—Back pain—Temozolomide—malignant glioma	0.0012	0.00968	CcSEcCtD
Pimecrolimus—Angioedema—Temozolomide—malignant glioma	0.00113	0.00914	CcSEcCtD
Pimecrolimus—Cough—Temozolomide—malignant glioma	0.00108	0.00873	CcSEcCtD
Pimecrolimus—CYP3A4—central nervous system—malignant glioma	0.00107	0.0117	CbGeAlD
Pimecrolimus—Arthralgia—Temozolomide—malignant glioma	0.00106	0.00852	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00105	0.00846	CcSEcCtD
Pimecrolimus—Oedema—Carmustine—malignant glioma	0.00105	0.00845	CcSEcCtD
Pimecrolimus—Infection—Carmustine—malignant glioma	0.00104	0.00839	CcSEcCtD
Pimecrolimus—Oedema—Temozolomide—malignant glioma	0.00101	0.00817	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Temozolomide—malignant glioma	0.00101	0.00817	CcSEcCtD
Pimecrolimus—Infection—Temozolomide—malignant glioma	0.00101	0.00811	CcSEcCtD
Pimecrolimus—Nervous system disorder—Temozolomide—malignant glioma	0.000994	0.00801	CcSEcCtD
Pimecrolimus—Skin disorder—Temozolomide—malignant glioma	0.000984	0.00793	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000955	0.0077	CcSEcCtD
Pimecrolimus—Paraesthesia—Carmustine—malignant glioma	0.000942	0.00759	CcSEcCtD
Pimecrolimus—Dyspnoea—Carmustine—malignant glioma	0.000935	0.00753	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000923	0.00744	CcSEcCtD
Pimecrolimus—Paraesthesia—Temozolomide—malignant glioma	0.00091	0.00733	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Carmustine—malignant glioma	0.000905	0.00729	CcSEcCtD
Pimecrolimus—Dyspnoea—Temozolomide—malignant glioma	0.000903	0.00728	CcSEcCtD
Pimecrolimus—Pain—Carmustine—malignant glioma	0.000897	0.00723	CcSEcCtD
Pimecrolimus—Constipation—Carmustine—malignant glioma	0.000897	0.00723	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000875	0.00705	CcSEcCtD
Pimecrolimus—Pain—Temozolomide—malignant glioma	0.000867	0.00698	CcSEcCtD
Pimecrolimus—Constipation—Temozolomide—malignant glioma	0.000867	0.00698	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Carmustine—malignant glioma	0.000858	0.00691	CcSEcCtD
Pimecrolimus—Abdominal pain—Carmustine—malignant glioma	0.000829	0.00668	CcSEcCtD
Pimecrolimus—Body temperature increased—Carmustine—malignant glioma	0.000829	0.00668	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Temozolomide—malignant glioma	0.000829	0.00668	CcSEcCtD
Pimecrolimus—Urticaria—Temozolomide—malignant glioma	0.000805	0.00649	CcSEcCtD
Pimecrolimus—Abdominal pain—Temozolomide—malignant glioma	0.000801	0.00645	CcSEcCtD
Pimecrolimus—Body temperature increased—Temozolomide—malignant glioma	0.000801	0.00645	CcSEcCtD
Pimecrolimus—Hypersensitivity—Carmustine—malignant glioma	0.000773	0.00622	CcSEcCtD
Pimecrolimus—Hypersensitivity—Temozolomide—malignant glioma	0.000747	0.00602	CcSEcCtD
Pimecrolimus—Diarrhoea—Carmustine—malignant glioma	0.000717	0.00578	CcSEcCtD
Pimecrolimus—Pruritus—Temozolomide—malignant glioma	0.000717	0.00578	CcSEcCtD
Pimecrolimus—Diarrhoea—Temozolomide—malignant glioma	0.000693	0.00559	CcSEcCtD
Pimecrolimus—Vomiting—Carmustine—malignant glioma	0.000667	0.00537	CcSEcCtD
Pimecrolimus—Rash—Carmustine—malignant glioma	0.000661	0.00533	CcSEcCtD
Pimecrolimus—Dermatitis—Carmustine—malignant glioma	0.000661	0.00532	CcSEcCtD
Pimecrolimus—Headache—Carmustine—malignant glioma	0.000657	0.00529	CcSEcCtD
Pimecrolimus—Vomiting—Temozolomide—malignant glioma	0.000644	0.00519	CcSEcCtD
Pimecrolimus—Rash—Temozolomide—malignant glioma	0.000639	0.00515	CcSEcCtD
Pimecrolimus—Dermatitis—Temozolomide—malignant glioma	0.000638	0.00514	CcSEcCtD
Pimecrolimus—Headache—Temozolomide—malignant glioma	0.000635	0.00512	CcSEcCtD
Pimecrolimus—Nausea—Carmustine—malignant glioma	0.000623	0.00502	CcSEcCtD
Pimecrolimus—Nausea—Temozolomide—malignant glioma	0.000602	0.00485	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—HEY1—malignant glioma	0.000102	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTPN11—malignant glioma	0.000102	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—malignant glioma	0.000102	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—malignant glioma	0.000102	0.000197	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—malignant glioma	0.000102	0.000197	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NOTCH1—malignant glioma	0.000102	0.000196	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FBXW7—malignant glioma	0.000101	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—malignant glioma	0.000101	0.000195	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—malignant glioma	0.0001	0.000193	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD80—malignant glioma	0.0001	0.000193	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—malignant glioma	0.0001	0.000192	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP3—malignant glioma	9.98e-05	0.000192	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD80—malignant glioma	9.97e-05	0.000192	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIST1H3B—malignant glioma	9.96e-05	0.000191	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—APC—malignant glioma	9.95e-05	0.000191	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN2B—malignant glioma	9.9e-05	0.00019	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGF—malignant glioma	9.88e-05	0.00019	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGF—malignant glioma	9.84e-05	0.000189	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—malignant glioma	9.82e-05	0.000189	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTPN11—malignant glioma	9.82e-05	0.000189	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTPN11—malignant glioma	9.78e-05	0.000188	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTK2—malignant glioma	9.61e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNA2—malignant glioma	9.6e-05	0.000185	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT2—malignant glioma	9.53e-05	0.000183	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—malignant glioma	9.46e-05	0.000182	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HES1—malignant glioma	9.44e-05	0.000182	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NCOR1—malignant glioma	9.39e-05	0.00018	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—BRAF—malignant glioma	9.36e-05	0.00018	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KRAS—malignant glioma	9.28e-05	0.000178	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CD—malignant glioma	9.15e-05	0.000176	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT2—malignant glioma	9.15e-05	0.000176	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT2—malignant glioma	9.11e-05	0.000175	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAG2—malignant glioma	9.09e-05	0.000175	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—malignant glioma	9.06e-05	0.000174	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDGFRA—malignant glioma	8.99e-05	0.000173	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—malignant glioma	8.79e-05	0.000169	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CD—malignant glioma	8.79e-05	0.000169	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—FGF2—malignant glioma	8.76e-05	0.000168	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CD—malignant glioma	8.75e-05	0.000168	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SPP1—malignant glioma	8.73e-05	0.000168	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—PIK3CA—malignant glioma	8.53e-05	0.000164	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGF2—malignant glioma	8.41e-05	0.000162	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGF2—malignant glioma	8.38e-05	0.000161	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTK2—malignant glioma	8.36e-05	0.000161	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—BCL2—malignant glioma	8.32e-05	0.00016	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TERT—malignant glioma	8.27e-05	0.000159	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MDM2—malignant glioma	8.2e-05	0.000158	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RAF1—malignant glioma	8.17e-05	0.000157	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—ERBB2—malignant glioma	8.08e-05	0.000155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PDGFB—malignant glioma	8.08e-05	0.000155	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR1—malignant glioma	8.03e-05	0.000154	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CB—malignant glioma	7.98e-05	0.000153	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN2B—malignant glioma	7.95e-05	0.000153	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HIF1A—malignant glioma	7.91e-05	0.000152	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—MDM2—malignant glioma	7.87e-05	0.000151	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RAF1—malignant glioma	7.85e-05	0.000151	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MDM2—malignant glioma	7.84e-05	0.000151	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PDGFRA—malignant glioma	7.82e-05	0.00015	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RAF1—malignant glioma	7.81e-05	0.00015	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-B—malignant glioma	7.77e-05	0.000149	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ERBB2—malignant glioma	7.76e-05	0.000149	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—ERBB2—malignant glioma	7.73e-05	0.000149	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—H3F3A—malignant glioma	7.69e-05	0.000148	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CB—malignant glioma	7.66e-05	0.000147	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CAV1—malignant glioma	7.65e-05	0.000147	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CB—malignant glioma	7.63e-05	0.000147	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCR3—malignant glioma	7.62e-05	0.000146	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HES1—malignant glioma	7.58e-05	0.000146	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KDR—malignant glioma	7.57e-05	0.000145	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—malignant glioma	7.56e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NCOR1—malignant glioma	7.54e-05	0.000145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—YWHAE—malignant glioma	7.41e-05	0.000142	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTRK2—malignant glioma	7.41e-05	0.000142	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FLT1—malignant glioma	7.38e-05	0.000142	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—DUSP6—malignant glioma	7.34e-05	0.000141	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—F2—malignant glioma	7.28e-05	0.00014	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FN1—malignant glioma	7.28e-05	0.00014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JAG1—malignant glioma	7.25e-05	0.000139	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH3—malignant glioma	7.22e-05	0.000139	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PDGFRA—malignant glioma	7.22e-05	0.000139	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BAD—malignant glioma	7.2e-05	0.000138	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-A—malignant glioma	7.2e-05	0.000138	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NOTCH1—malignant glioma	7.13e-05	0.000137	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FBXW7—malignant glioma	7.1e-05	0.000137	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PDGFB—malignant glioma	7.02e-05	0.000135	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR1—malignant glioma	6.99e-05	0.000134	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CD80—malignant glioma	6.98e-05	0.000134	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CG—malignant glioma	6.97e-05	0.000134	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APC—malignant glioma	6.97e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BDKRB2—malignant glioma	6.97e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—malignant glioma	6.97e-05	0.000134	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—malignant glioma	6.89e-05	0.000133	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGF—malignant glioma	6.89e-05	0.000132	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTPN11—malignant glioma	6.85e-05	0.000132	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—malignant glioma	6.64e-05	0.000128	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HLA-A—malignant glioma	6.64e-05	0.000128	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—malignant glioma	6.62e-05	0.000127	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—malignant glioma	6.59e-05	0.000127	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BRAF—malignant glioma	6.55e-05	0.000126	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PDGFB—malignant glioma	6.49e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH2—malignant glioma	6.48e-05	0.000125	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR1—malignant glioma	6.45e-05	0.000124	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT2—malignant glioma	6.38e-05	0.000123	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIF1A—malignant glioma	6.35e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KNG1—malignant glioma	6.34e-05	0.000122	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BAD—malignant glioma	6.26e-05	0.00012	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—COX8A—malignant glioma	6.19e-05	0.000119	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CAV1—malignant glioma	6.15e-05	0.000118	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CD—malignant glioma	6.13e-05	0.000118	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD80—malignant glioma	6.07e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NTRK1—malignant glioma	6.04e-05	0.000116	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGF—malignant glioma	5.99e-05	0.000115	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTPN11—malignant glioma	5.96e-05	0.000115	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—malignant glioma	5.89e-05	0.000113	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—FGF2—malignant glioma	5.87e-05	0.000113	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BAD—malignant glioma	5.78e-05	0.000111	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NOTCH1—malignant glioma	5.72e-05	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP3—malignant glioma	5.62e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD80—malignant glioma	5.61e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—malignant glioma	5.6e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APC—malignant glioma	5.6e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN2B—malignant glioma	5.57e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT2—malignant glioma	5.55e-05	0.000107	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGF—malignant glioma	5.53e-05	0.000106	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTPN11—malignant glioma	5.5e-05	0.000106	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MDM2—malignant glioma	5.49e-05	0.000106	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—malignant glioma	5.48e-05	0.000105	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RAF1—malignant glioma	5.47e-05	0.000105	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—malignant glioma	5.41e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTK2—malignant glioma	5.41e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—malignant glioma	5.38e-05	0.000103	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—malignant glioma	5.36e-05	0.000103	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—malignant glioma	5.34e-05	0.000103	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—malignant glioma	5.33e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HES1—malignant glioma	5.31e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—malignant glioma	5.29e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NCOR1—malignant glioma	5.28e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BRAF—malignant glioma	5.26e-05	0.000101	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ASMT—malignant glioma	5.26e-05	0.000101	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—malignant glioma	5.13e-05	9.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT2—malignant glioma	5.12e-05	9.85e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGF2—malignant glioma	5.1e-05	9.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—malignant glioma	5.08e-05	9.77e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—malignant glioma	5.06e-05	9.73e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFRA—malignant glioma	5.06e-05	9.72e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BCAN—malignant glioma	4.95e-05	9.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—malignant glioma	4.92e-05	9.46e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—malignant glioma	4.91e-05	9.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SPP1—malignant glioma	4.91e-05	9.44e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—malignant glioma	4.91e-05	9.43e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—malignant glioma	4.86e-05	9.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2—malignant glioma	4.85e-05	9.32e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—malignant glioma	4.8e-05	9.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MDM2—malignant glioma	4.78e-05	9.18e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RAF1—malignant glioma	4.76e-05	9.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGF2—malignant glioma	4.71e-05	9.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—malignant glioma	4.71e-05	9.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—malignant glioma	4.67e-05	8.98e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—malignant glioma	4.65e-05	8.95e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—malignant glioma	4.65e-05	8.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—malignant glioma	4.65e-05	8.93e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—malignant glioma	4.64e-05	8.93e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—malignant glioma	4.62e-05	8.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PDGFB—malignant glioma	4.54e-05	8.73e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR1—malignant glioma	4.52e-05	8.69e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—malignant glioma	4.45e-05	8.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MDM2—malignant glioma	4.41e-05	8.48e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RAF1—malignant glioma	4.39e-05	8.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—malignant glioma	4.35e-05	8.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CAV1—malignant glioma	4.3e-05	8.27e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—malignant glioma	4.29e-05	8.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL1B—malignant glioma	4.28e-05	8.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—malignant glioma	4.27e-05	8.2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—malignant glioma	4.26e-05	8.18e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—malignant glioma	4.25e-05	8.17e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—malignant glioma	4.17e-05	8.02e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—malignant glioma	4.13e-05	7.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—F2—malignant glioma	4.1e-05	7.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FN1—malignant glioma	4.1e-05	7.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BAD—malignant glioma	4.05e-05	7.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—malignant glioma	4.01e-05	7.72e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH1—malignant glioma	4.01e-05	7.71e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—IDH2—malignant glioma	3.99e-05	7.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—malignant glioma	3.97e-05	7.64e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CD80—malignant glioma	3.93e-05	7.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APC—malignant glioma	3.92e-05	7.54e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—malignant glioma	3.92e-05	7.54e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGF—malignant glioma	3.88e-05	7.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTPN11—malignant glioma	3.85e-05	7.41e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—malignant glioma	3.84e-05	7.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—malignant glioma	3.81e-05	7.33e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—malignant glioma	3.8e-05	7.3e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—malignant glioma	3.75e-05	7.21e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2B6—malignant glioma	3.75e-05	7.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—malignant glioma	3.71e-05	7.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BRAF—malignant glioma	3.68e-05	7.08e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—malignant glioma	3.59e-05	6.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT2—malignant glioma	3.59e-05	6.9e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—malignant glioma	3.54e-05	6.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—malignant glioma	3.45e-05	6.63e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—IDH1—malignant glioma	3.43e-05	6.59e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SPHK1—malignant glioma	3.32e-05	6.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—malignant glioma	3.32e-05	6.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF2—malignant glioma	3.3e-05	6.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—malignant glioma	3.26e-05	6.27e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—malignant glioma	3.26e-05	6.26e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2C18—malignant glioma	3.25e-05	6.25e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—malignant glioma	3.15e-05	6.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MDM2—malignant glioma	3.09e-05	5.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—malignant glioma	3.08e-05	5.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—malignant glioma	3.08e-05	5.92e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RAF1—malignant glioma	3.08e-05	5.92e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—malignant glioma	3.04e-05	5.85e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—malignant glioma	3.01e-05	5.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—malignant glioma	3e-05	5.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—malignant glioma	2.89e-05	5.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—malignant glioma	2.85e-05	5.47e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—malignant glioma	2.83e-05	5.45e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—malignant glioma	2.76e-05	5.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—malignant glioma	2.76e-05	5.3e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—malignant glioma	2.66e-05	5.11e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTT1—malignant glioma	2.63e-05	5.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—malignant glioma	2.62e-05	5.03e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—malignant glioma	2.61e-05	5.02e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—malignant glioma	2.6e-05	4.99e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS1—malignant glioma	2.46e-05	4.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—malignant glioma	2.34e-05	4.51e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—malignant glioma	2.32e-05	4.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—malignant glioma	2.31e-05	4.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—BCHE—malignant glioma	2.29e-05	4.4e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SLC5A5—malignant glioma	2.26e-05	4.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—malignant glioma	2.16e-05	4.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—malignant glioma	2.14e-05	4.11e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—malignant glioma	2.11e-05	4.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—malignant glioma	1.99e-05	3.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—malignant glioma	1.83e-05	3.52e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTP1—malignant glioma	1.82e-05	3.5e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAT—malignant glioma	1.77e-05	3.41e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—malignant glioma	1.77e-05	3.41e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOR1—malignant glioma	1.67e-05	3.22e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—malignant glioma	1.5e-05	2.88e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAV1—malignant glioma	1.37e-05	2.62e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.24e-05	2.39e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPARG—malignant glioma	1.2e-05	2.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.09e-05	2.1e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—malignant glioma	9.53e-06	1.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—malignant glioma	9.44e-06	1.82e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—malignant glioma	8.23e-06	1.58e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—malignant glioma	5.81e-06	1.12e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—malignant glioma	4.75e-06	9.12e-06	CbGpPWpGaD
